Answers are grounded in this paper and cite their sources.
In this invention, a novel cancer drug is formed by Cu(II) and Fe(III) binding the medicinal molecule Paclitaxel (PAC). This complexation increases the water solubility of the taxane, alters the structure so resistance mechanisms do not recognize it, and adds additional toxicity. The copper (II) species can generate reactive oxidation species (ROS) and randomly bind and distort proteins within a cancer cell. Cu(II) also plays a role in accelerating angiogenesis and creates a Trojan horse effect that increases its uptake rate by the cancer cells. The empirical formula for the complex is CuxFeyPAC1, where X + Y equals a value between 0 and 10.
No takes yet. Share an insight, caveat, or question.
Manning et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: